Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 12

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 12
---
 ICC resistant to previous FGFR inhibitors.

Our FGF19+ Program- TYRA-430 for Hepatocellular Carcinoma

Fibroblast growth factor 19 (FGF19) is a post-prandial enterohepatic hormone that signals through FGFR4 and its associated co-receptor Klotho Beta (KLB) to exert its normal cellular functions. In certain cancers, FGF19 is aberrantly expressed due to focal chromosomal amplifications or epigenetic mechanisms, promoting tumor cells to become dependent on the FGFR4/KLB/FGF19 oncogenic axis. Recent insights into FGF/FGFR signaling in HCC have indicated an important bypass mechanism in FGFR3, which shares the KLB coreceptor.

TYRA-430 was designed to be biased for FGFR4 and FGFR3 over the FGFR1 and FGFR2 isoforms specifically to address the FGF19 signaling pathway, while also potentially limiting side effects due to inhibition of FGFR1 and FGFR2, as well as to address acquired resistance mutations that have limited the efficacy of previous FGFR4-specific inhibitors. TYRA-430 will be initially studied in SURF431, a global Phase 1 multicenter, open-label, study in advanced HCC and other solid tumors with activating FGF/FGFR pathway aberrations (SURF431). We expect to dose the first patient in this study in the second quarter of 2025.

Our Pipeline

4

Our Strategy 

Our mission is to improve outcomes for patients living with cancer and genetically defined conditions.  We are executing on our mission by focusing on our three strategic pillars: a novel SNÅP platform; an expanding and advancing pipeline; and building a leading company around FGFR biology.  With this strategy, our goal is the discovery, development and commercialization of next-generation precision small molecules against clinically validated targets to treat a wide range of indications currently lacking adequate treatment options.  

The elements of our strategy to achieve this goal are to:

1.Advance our lead product candidate, TYRA-300, in bladder cancer and skeletal conditions;

2.Advance our early-stage clinical pipeline and maintain our position as a leader in our initial focus area of FGFR biology; and

3.Harness the power of our SNÅP platform to expand our pipeline of next-generation precision medicines for oncology and rare disease indications within FGFR biology and potentially other target areas of interest. 

All of our assets have been developed in